Natural products and ion channel pharmacology

Future Medicinal Chemistry

Volumn 2, Issue 5, 2010, Pages 731-744

  Teichert, Russell W ^a   Olivera, Baldomero M ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BUNGAROTOXIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONOTOXIN; EXENDIN 4; GLUTAMATE RECEPTOR ANTAGONIST; NATURAL PRODUCT; NICOTINIC ACID; NICOTINIC RECEPTOR BLOCKING AGENT; OMEGA CONOTOXIN MVIIA; POTASSIUM CHANNEL BLOCKING AGENT; SCORPION VENOM; SEA ANEMONE TOXIN; SHK PEPTIDE; SNAIL VENOM; SODIUM CHANNEL BLOCKING AGENT; SPIDER VENOM; TM 601; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AUTOIMMUNE DISEASE; BINDING SITE; CLADISTICS; CONUS SNAIL; DRUG INDUSTRY; DRUG RECEPTOR BINDING; DRUG RESEARCH; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GLIOMA; HYPERTENSION; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAIN; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; SPECIES DIFFERENCE;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL PRODUCTS; DRUG DISCOVERY; HUMANS; ION CHANNELS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA;

EID: 77953391048     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.31     Document Type: Review

References (70)

1. Cuatrecasas P. Drug discovery in jeopardy. J. Clin. Investig. 116 (11), 2837-2842 (2006).
2. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 (8), 711-715 (2004).
3. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8 (12), 959-968 (2009).
4. PhRMA. Pharmaceutical industry profile 2009. America, PRaMo, PhRMA, Washington, DC, USA (2009).
5. Hirschler B. Drugmakers face $140 billion patent 'Cliff'. In: Reuters. London, UK (2007)
6. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4 (11), 682-690 (2008).
7. Molinari G. Natural products in drug discovery: present status and perspectives. Adv. Exp. Med. Biol. 655, 13-27 (2009).
8. Newman DJ. Natural products as leads to potential drugs: an old process or the new hope for drug discovery? J. Med. Chem. 51 (9), 2589-2599 (2008).
9. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70 (3), 461-477 (2007).
10. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J. Nat. Prod. 66, 1022-1037 (2003).
11. Gorse AD. Diversity in medicinal chemistry space. Curr. Top. Med. Chem. 6 (1), 3-18 (2006).
12. Bohacek RS, McMartin C, Guida WC. The art and practice of structure-based drug design: a molecular modeling perspective. Med. Res. Rev. 16 (1), 3-50 (1996).
13. Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4 (3), 206-220 (2005).
14. Li J W, Vederas JC. Drug discovery and natural products: end of an era or an endless frontier? Science 325 (5937), 161-165 (2009).
15. Soejarto DD, Fong HH, Tan GT et al. Ethnobotany/ethnopharmacology and mass bioprospecting: issues on intellectual property and benefit-sharing. J. Ethnopharmacol. 100 (1-2), 15-22 (2005).
16. Chang CC, Lee CY. Isolation of neurotoxins from the venom of bungarus multicinctus and their modes of neuromuscular blocking action. Arch. Int. Pharmacodyn. Ther. 144, 241-257 (1963).
17. Biass D, Dutertre S, Gerbault A et al. Comparative proteomic study of the venom of the piscivorous cone snail conus consors. J. Proteomics 72 (2), 210-218 (2009).
18. Escoubas P, King GF. Venomics as a drug discovery platform. Expert Rev. Proteomics 6 (3), 221-224 (2009).
19. Escoubas P, Sollod B, King GF. Venom landscapes: mining the complexity of spider venoms via a combined cDNA and mass spectrometric approach. Toxicon 47 (6), 650-663 (2006).
20. Corpuz GP, Jacobsen RB, Jimenez EC et al. Definition of the M-conotoxin superfamily: characterization of novel peptides from Molluscivorous conus venoms. Biochemistry 44 (22), 8176-8186 (2005).
21. Espiritu D J D, Watkins M, Dia-Monje V, Cartier GE, Cruz LJ, Olivera BM. Venomous cone snails: molecular phylogeny and the generation of toxin diversity. Toxicon. 39, 1899-1916 (2001).
22. Olivera BM, Teichert RW. Diversity of the neurotoxic conus peptides: a model for concerted pharmacological discovery. Mol. Intervent. 7 (5), 251-260 (2007).
23. Santos AD, McIntosh JM, Hillyard DR, Cruz LJ, Olivera BM. The α-superfamily of conotoxins: structural and functional divergence. J. Biol. Chem. 279, 17596-17606 (2004).
24. Escoubas P, Quinton L, Nicholson GM. Venomics: unravelling the complexity of animal venoms with mass spectrometry. J. Mass Spectrom. 43 (3), 279-295 (2008).
25. Ueberheide BM, Fenyo D, Alewood PF, Chait BT. Rapid sensitive analysis of cysteine rich peptide venom components. Proc. Natl Acad. Sci. USA 106 (17), 6910-6915 (2009).
26. Miljanich GP. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain. Curr. Med. Chem. 11, 3029-3040 (2004).
27. Prommer E. Ziconotide: a new option for refractory pain. Drugs Today (Barc), 42 (6), 369-378 (2006).
28. Olivera BM, Cruz LJ, de Santos V et al. Neuronal Ca channel antagonists. Discrimination between Ca channel subtypes using w-conotoxin from conus magus venom. Biochemistry 26, 2086-2090 (1987).
29. Olivera BM, Gray WR, Zeikus R et al. Peptide neurotoxins from fish-hunting cone snails. Science 230, 1338-1343 (1985).
30. Olivera BM, Miljanich G, Ramachandran J, Adams ME. Calcium channel diversity and neurotransmitter release: the ω-conotoxins and ω-agatoxins. Annu. Rev. Biochem. 63, 823-867 (1994).
31. Yoshikami D, Bagabaldo Z, Olivera BM. The inhibitory effects of ω-conotoxins on calcium channels and synapses. Ann. NY Acad. Sci. 560, 230-248 (1989).
32. Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol. Rev. 231 (1), 59-87 (2009).
33. v1.3 potassium channels as a therapeutic target in multiple sclerosis. Expert Opin. Ther. Targets, 13 (8), 909-924 (2009).
34. Pennington MW, Byrnes ME, Zaydenberg I et al. Chemical synthesis and characterization of Shk toxin: a potent potassium channel inhibitor from a sea anemone. Int. J. Pept. Protein Res. 46 (5), 354-358 (1995).
35. Castañeda O, Sotolongo V, Amor AM et al. Characterization of a potassium channel toxin from the caribbean sea anemone Stichodactyla helianthus. Toxicon 33, 603-613 (1995).
36. + channel in effector memory T cells as new target for MS. J. Clin. Invest. 111 (11), 1703-1713 (2003).
37. v1.3-specifc immunosuppressive polypeptide. J. Biol. Chem. 273 (49), 32697-32707 (1998).
38. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc. Natl Acad. Sci. USA 98 (24), 13942-13947 (2001).
39. v1.3 channel in T lymphocytes. Mol. Pharmacol. 75 (4), 762-773 (2009).
40. Press Release. Kineta acquires novel drug candidates from airmid for potential treatment of multiple sclerosis, Type 1 diabetes and other autoimmune diseases. Kineta, Inc., Seattle, Washington, USA, July 2009.
41. Fusetani N, Kem W. Marine toxins: an overview. Prog. Mol. Subcell Biol. 46, 1-44 (2009).
42. Nakao Y, Fusetani N. Enzyme inhibitors from marine invertebrates. J. Nat. Prod. 70 (4), 689-710 (2007).
43. Röckel D, Korn W, Kohn AJ. Manual of the living conidae. Verlag Christa Hemmen, Wiesbaden, Germany (1995).
44. Duda Jr TE, Palumbi SR. Gene expression and feeding ecology: evolution of piscivory in the venomous gastropod genus conus. Proc. Royal Soc. London 271, 1165-1174 (2004).
45. Imperial J, Silverton N, Olivera BM et al. Using chemistry to reconstruct evolution: on the origins of fish-hunting in venomous cone snails. Proc. Am. Phil. Soc. 151, 185-200 (2007).
46. Olivera BM. Conus venom peptides, receptor and ion channel targets and drug design: 50 million years of neuropharmacology. Mol. Biol. Cell 8, 2101-2109 (1997).
47. Olivera BM, Cruz LJ. Conotoxins, in retrospect. Toxicon 39, 7-14 (2001).
48. Terlau H, Shon K, Grilley M, Stocker M, Stühmer W, Olivera BM. Strategy for rapid immobilization of prey by a fish-hunting cone snail. Nature 381, 148-151 (1996).
49. 2+ channels. 7Neuron 9, 69-77 (1992).
50. Twede VD, Miljanich G, Olivera BM, Bulaj G. Neuroprotective and cardioprotective conopeptides: an emerging class of drug leads. Curr. Opin. Drug Discov. Devel. 12 (2), 231-239 (2009).
51. Sato K, Ishida Y, Wakamatsu K et al. Active site u-conotoxin GIIIA, a peptide blocker of muscle sodium channels. J. Biol. Chem. 266, 16989-16991 (1991).
52. Barbier J, Lamthanh H, Le Gall F et al. A δ-conotoxin from conus ermineus venom inhibits inactivation in vertebrate neuronal Na+ channels but not in skeletal and cardiac muscles. J. Biol. Chem. 279, 4680-4685 (2004).
53. McIntosh JM, Cruz LJ, Hunkapiller MW, Gray WR, Olivera BM. Isolation and structure of a peptide toxin from the marine snail conus magus. Arch. Biochem. Biophys. 218, 329-334 (1982).
54. Hopkins C, Grilley M, Miller C et al. A new family of conus peptides targeted to the nicotinic acetylcholine receptor. J. Biol. Chem. 270, 22361-22367 (1995).
55. Zafaralla GC, Ramilo C, Gray WR, Karlstrom R, Olivera BM, Cruz LJ. Phylogenetic specificity of cholinergic ligands: A-conotoxin S1. Biochemistry 27, 7102-7105 (1988).
56. Myers RA, Zafaralla GC, Gray WR, Abbott J, Cruz LJ, Olivera BM. α-conotoxins, small peptide probes of nicotinic acetylcholine receptors. Biochemistry 30, 9370-9377 (1991).
57. Ramilo CA, Zafaralla GC, Nadasdi L et al. Novel α- and ω-conotoxins from conus striatus venom. Biochemistry 31, 9919-9926 (1992).
58. Jacobsen R, Yoshikami D, Ellison M et al. Differential targeting of nicotinic acetylcholine receptors by novel a-conotoxins. J. Biol. Chem. 272, 22531-22537 (1997).
59. Shon K, Koerber SC, Rivier JE, Olivera BM, McIntosh JM. Three-dimensional solution structure of α-conotoxin MII, an α3β2 neuronal nicotinic acetylcholine receptor-targeted ligand. Biochemistry 36, 15693-15700 (1997).
60. Zhang MM, Fiedler B, Green BR et al. Structural and functional diversities among mu-conotoxins targeting TTX-resistant sodium channels. Biochemistry 45 (11), 3723-3732 (2006).
61. Shon K, Olivera BM, Watkins M et al. μ-conotoxin PIIIA, a new peptide for discriminating among tetrodotoxin-sensitive Na channel subtypes. J. Neurosci. 18, 4473-4481 (1998).
62. Bulaj G, West PJ, Garrett JE et al. Novel conotoxins from conus striatus and conus kinoshitai selectively block ttx-resistant sodium channels. Biochemistry 44, 7259-7265 (2005).
63. Leipold E, Hansel A, Olivera BM, Terlau H, Heinemann SH. Synergistic voltage sensor trapping of sodium channels by δ-conotoxins and scorpion α-toxins. FEBS Lett. (2005) (In Press).
64. Shon K, Grilley MM, Marsh M et al. Purification, characterization and cloning of the lockjaw peptide from conus purpurascens venom. Biochemistry 34, 4913-4918 (1995).
65. Bayrhuber M, Vijayan V, Ferber M et al. Conkunitzin-S1 is the frst member of a new kunitz-type neurotoxin family. Structural and functional characterization. J. Biol. Chem. 280 (25), 23766-23770 (2005).
66. Walker CS, Jensen S, Ellison M et al. A novel conus snail polypeptide causes excitotoxicity by blocking desensitization of AMPA receptors. Curr. Biol. 19, 1-9 (2009).
67. Groebe DR, Dumm JM, Levitan ES, Abramson SN. α-conotoxins selectively inhibit one of the two acetylcholine binding sites of nicotinic receptors. Mol. Pharmacol. 48, 105-111 (1995).
68. Terlau H, Olivera BM. Conus venoms: a rich source of novel ion channel-targeted peptides. Physiol. Rev. 84, 41-68 (2004).
69. Adams DJ, Smith AB, Schroeder CI, Yasuda T, Lewis RJ. ω-conotoxin CVID inhibits a pharmacologically distinct voltage-sensitive calcium channel associated with transmitter release from preganglionic nerve terminals (PDB ID. 1TTK). J. Biol. Chem. 278, 4057-4062 (2003).
70. Tudor JE, Pallaghy PK, Pennington MW, Norton RS. Solution structure of Shk toxin, a novel potassium channel inhibitor from a sea anemone (PDB ID. 1ROO). Nat. Struct. Biol. 3, 317-320 (1996).